FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

ReachMD Healthcare Image
RestartResume
    The FDA found no significant increase in risk of serious asthma outcomes combining long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS)
    • Overview

      The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. 

      A link to the full communication detailing information for health care professionals and the Data Summary can be found at www.fda.gov/DrugSafetyCommunications.

      Released 12/20/2017

    Facebook Comments

    Register

    We’re glad to see you’re enjoying Prova Education…
    but how about a more personalized experience?

    Register for free